English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/122572
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Control of FLIP L expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells

AuthorsYerbes, Rosario ; López-Rivas, Abelardo ; Reginato, Mauricio J.; Palacios, Carmen
Issue Date22-Jun-2012
PublisherNature Publishing Group
CitationCell Death and Differentiation 19: 1908-1916 (2012)
AbstractIncreased activation of the epidermal growth factor receptor (EGFR) is frequently observed in tumors, and inhibition of the signaling pathways originated in the EGFR normally renders tumor cells more sensitive to apoptotic stimuli. However, we show that inhibition of EGFR signaling in non-transformed breast epithelial cells by EGF deprivation or gefitinib, an inhibitor of EGFR tyrosine kinase, causes the upregulation of the long isoform of caspase-8 inhibitor FLICE-inhibitory protein (FLIP L) and makes these cells more resistant to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We demonstrate that the extracellular signal-regulated kinase (ERK)1/2 pathway plays a pivotal role in the regulation of FLIP L levels and sensitivity to TRAIL-induced apoptosis by EGF. Upregulation of FLIP L upon EGF deprivation correlates with a decrease in c-Myc levels and c-Myc knockdown by siRNA induces FLIP L expression. FLIP L upregulation and resistance to TRAIL in EGF-deprived cells are reversed following activation of an estrogen activatable form of c-Myc (c-Myc-ER). Finally, constitutive activation of the ERK1/2 pathway in HER2/ERBB2-transformed cells prevents EGF deprivation-induced FLIP L upregulation and TRAIL resistance. Collectively, our results suggest that a regulated ERK1/2 pathway is crucial to control FLIP L levels and sensitivity to TRAIL in non-transformed cells, and this mechanism may explain the increased sensitivity of tumor cells to TRAIL, in which the ERK1/2 pathway is frequently deregulated. © 2012 Macmillan Publishers Limited All rights reserved.
Publisher version (URL)http://dx.doi.org/10.1038/cdd.2012.78
Identifiersissn: 1350-9047
e-issn: 1476-5403
Appears in Collections:(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.